July 14, 2026/
Insulin Syringe Safety, Drug-Drug Interactions with Valproic Acid and Methotrexate, and Denosumab-Induced Mineral Metabolism Disturbances
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Insulin Syringe Safety, Drug-Drug Interactions with Valproic Acid and Methotrexate, and Denosumab-Induced Mineral Metabolism Disturbances
The Egyptian Drug Authority (EDA) published its third version of the Good Pharmacovigilance Practice (GVP) guideline in 2026, representing a significant evolution in Egypt's pharmacovigilance regulatory...
Pancreatin and HEV Transmission, Amoxicillin-Associated Encephalopathy, SGLT2 Inhibitors and Lichen Sclerosus, GLP-1 RA Peripheral Neuropathies and Volvulus, and More
